Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective - a Commentary by Clark, Ian & Vissel, Bryce
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iern20
Expert Review of Neurotherapeutics
ISSN: 1473-7175 (Print) 1744-8360 (Online) Journal homepage: https://www.tandfonline.com/loi/iern20
Neurodegenerative disease treatments by direct
TNF reduction, SB623 cells, maraviroc and irisin
and MCC950, from an inflammatory perspective –
a Commentary
I A Clark & B Vissel
To cite this article: I A Clark & B Vissel (2019) Neurodegenerative disease treatments by
direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory
perspective – a Commentary, Expert Review of Neurotherapeutics, 19:6, 535-543, DOI:
10.1080/14737175.2019.1618710
To link to this article:  https://doi.org/10.1080/14737175.2019.1618710
© 2019 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Accepted author version posted online: 16
May 2019.
Published online: 24 May 2019.
Submit your article to this journal 
Article views: 403
View Crossmark data
REVIEW
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ABSTRACT
Introduction: The importance of excessive cerebral tumor necrosis factor (TNF) concentrations as one of
the central tenets of the pathogenesis of the neurodegenerative diseases is now widely known, but
variably accepted.
Areas covered: Here we update the field by including material that is freely available on the large
databases, particularly PubMed. We include the therapeutic outcomes with etanercept (a widely used
specific anti-TNF biological), XPro1595 (a new double negative TNF inhibitor), 3,61-dithiothalidomide,
implanted SB623 stem cells, maraviroc (a CCR5 inhibitor used to treat AIDS), MCC950 (an NLRP3 inhibitor),
and changes in the hormone irisin.
Expert opinion: Remarkably, considering the ample literature that links SB623 cells, maraviroc, MCC950
and irisin to TNF, these publications do not mention this cytokine, and therefore not their implicit
involvement with controlling its cerebral levels. With regard to developments demonstrated by MCC950,
we note that DAMPs and PAMPs recognize and activate both TLRs and inflammasomes in these disease
states. Here, as in other illnesses, data suggests that preventing a pathogenic interaction could be achieved
through shutting down either of these arms of innate immunity.
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1. Background
A research perspective of neurodegenerative diseases that
regards proteinaceous markers in brain sections to be disease-
specific, and therefore useful as diagnostic tools that can also
define mechanisms for the various clinical entities, has now
almost gone. With it has largely gone the perception of funda-
mental differences inmechanisms, as distinct from emphasis and
anatomical locations of events in each of these entities. Often
this enlightenment was not so much through new knowledge,
but an awareness that one could cast the net much wider and
glean information that had been available for some time. The
‘traditional’ neurodegenerative diseases provide good examples
of this. Amyloid beta (Aβ) deposits and tau tangles are found not
only in Alzheimer’s disease (AD) brains but across the neurode-
generative disease spectrum. Tauopathy, for example, has
recently been noted to have been documented in 28 different
neurodegenerative states [1], a far cry from its original, at the
time implying specific, role in AD. Others have recently consid-
ered the pathways common to various neurodegenerative dis-
eases in terms of phenotypic networks rather than clinical
syndromes [2].
As well as tauopathy, cerebral Aβ and α-synuclein (αSyn)
deposition are remarkably widespread, including being histolo-
gically evident in the changes brought on by a stroke, traumatic
brain injury (TBI), cardiac arrest, and lead (Pb) poisoning, as we
have discussed previously [3]. While Parkinson’s disease (PD)
has been the archetypal focus for α-Syn research, this protein
has also been closely correlated with severity in AD, correlating
better, indeed, than Aβ or tau when all are in their soluble
forms [4]. Likewise, the transactive response (TAR) DNA-binding
protein with a molecular weight of 43 kDa (TDP-43), originally
identified as an intracellular ubiquitin-positive inclusion, is now
the newest member of the growing list of neurodegenerative
proteinopathies [5]. It was initially regarded as an important link
between one form of frontotemporal lobar degeneration (FTLD)
and amyotrophic lateral sclerosis (ALS). Subsequently, TDP-43
has been accepted to be present in most AD brains [6], as well
as in many aged brains that do not meet the criteria defining
FTLD [7]. In addition, other markers first described in other
neurodegenerative states, and once regarded as unique to
them, can be present in FTLD and ALS [8–10].
We and others have previously written about neurodegen-
erative diseases in general from an inflammatory perspective, in
particular, the harmfulness of chronically increased cerebral
levels of signaling cytokines that distort signaling pathways,
thus harming neurotransmission, mitochondrial function, and
cell viability [11–17]. In this Commentary, we note that the
literature on therapeutic approaches directly addressing TNF
reduction in neurodegenerative diseases now has a twelve-year
history, with use of a specific anti-TNF biological [18] soon
spreading to patients and models of both stroke and TBI. Five
years later literature employing 3,6-dithiothalidamide, an inhibi-
tor of TNF RNA, appeared in a TBI model [19] and soon after in AD
and stroke models, as we discuss later. A further three years later
an engineered double-negative form of TNF, XPro1595 [20], was
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used in a Parkinson’s disease (PD) model. Four more recent
papers discussed here are best categorized as indirect TNF reduc-
tion, some authors surprisingly not mentioning this well-known
cytokine and others perhaps not being aware of how it is linked
to their work. This series of texts begins, in the present text, with
a report of surgically implanting SB623 cells directly in the brain
of stroke patients [21], which we have previously discussed at
length [3]. Next, parenteral maraviroc [22] in stroke and TBI
mouse models, manipulated gene levels of irisin [23] in
mouse AD models, and oral MCC950 [24] for mouse PD models
are discussed. We largely restrict our comments on these four
recently emerged texts by summarising how they are linked
through their integration with the TNF literature.
2. TNF and IL-1 generation – DAMPs, PAMPs, TLRs,
NLRP3
The field of innate immunity, with which inflammation has
become closely affiliated, became much more comprehensible
through the advent of the concepts of pathogen-associated
molecular patterns (PAMPs) [25], danger-associated molecular
patterns (DAMPs) [26], and the transmembrane proteins referred
to as Toll-like receptors (TLRs) [27]. TLRs are a member of one of
the families of pattern recognition receptors (PRRs) that evolved
beforemuch of the rest of the immune system. Introducing these
novel overarching terms and concepts has succeeded in casting
a new light on the origins and consequences of the chronic
generation of cytokines such as TNF, with its profound effects
on disease pathogenesis as well as innate immunity. In practice,
PAMPs and DAMPs perform identical tasks – indeed the case has
beenmade to name them collectively as alarmins [28,29]. Having
been extremely useful in understanding pathogenesis overlaps
between systemic infectious and non-infectious states, these
concepts are also proving their worth in comprehending neuro-
degenerative disease.
Much evidence exists that the various disease markers dis-
cussed here activate TLRs on or in cerebral cellular components,
thereby chronically enhancing local levels of TNF and associated
cytokines. Being of host origin, these markers are termed DAMPs.
They can include hypomethylated host DNA (e.g. mtDNA released
after trauma [30]), normal host DNA hypomethylated by lead (Pb)
poisoning [31]), and High Mobility Group Box 1 (HMGB1). HMGB1
often arises from hypoxia, which enhances its release in many cell
types [32]). Non-infectious material such as air pollutants [33],
including diesel exhaust particles [34], are also referred to as
DAMPs. As noted above, other non-host material, such as mole-
cular patterns on pathogens that can enter the brain and cause
chronic infections [35,36] are termed PAMPs. Intriguingly, the
allergy literature regards biological allergens, while not technically
pathogens, are referred to as possessing PAMP activity [37].
As a preamble to a text we later discuss on MCC950 [24], we
comment briefly here on there being two parallel worlds of
PRRs, Toll-like receptors (TLRs), and the NOD-like receptors
(NLRs), both being as important in neurodegenerative diseases
as elsewhere [38,39]. One of these NLRs, NLRP3, is particularly
relevant here. TLRs, present across intra- or extracellular mem-
branes, which trigger TNF release, and NLRs, located within the
cytosol, are both activated by PAMPs and DAMPs. Activation of
certain NLRs leads to the formation of cytosolic protein com-
plexes termed inflammasomes, which regulate activation of
caspase-1, an enzyme that, through cleavage of their precursor
forms, generates active interleukin-1β (IL-1β) and IL-18.
3. The apparently central role of TNF in the
neurodegenerative diseases
3.1. Treatment with anti-TNF agents
Whenever, for brevity, TNF is discussed alone in this text, it
often implies the sense of other pro-inflammatory and anti-
inflammatory cytokines that are usually generated soon after-
ward, such as IL-1β and IL-18, when inflammasome activitation
has come into play. A primary driver function of TNF in these
cytokine families can be inferred from the massively successful
therapeutic use of anti-TNF biological agents in important sys-
temic clinical conditions, beginning with rheumatoid arthritis in
1994 [40]. Indeed, in 2013 Schett and co-authors made what we
see as a convincing case rationalizing why TNF should be
expected to be more central than other cytokines to inflamma-
tory disease pathogenesis [41].
As reviewed [42], for some years before interest in roles for
cerebral-origin TNF in neurodegenerative states arose, this cyto-
kine had been appreciated to be central to the pathogenesis of
systemic infectious and certain non-infectious diseases.
Experience with in vivo responses to specific anti-TNF biologicals
over the last 12 years has generated a strong case for this being
true for the important neurodegenerative diseases as well.
Unfortunately, the first direct evidence emerged at the height of
massive Pharma financial commitment to anti-Aβ trials in
human AD, and this drew most funding and therefore intellectual
effort in the field in this direction. Hence, the central role of excess
cerebral TNF was extremely slow in attracting a following.
Continuing failure of anti-Aβ trials, conceivably aided by over
a decade’s peer-reviewed criticism of their scientific implausibility
[43,44], eventually played a part in overcoming this reticence [45].
Nowadaysmuch literature points to the harmfulness of excess TNF
in the central nervous system through a combination of loss of
homeostasis, and therefore potentially reversible function loss, as
well as cell death. Initially this was through outcomes of adminis-
tering etanercept, a specific anti-TNF biological to AD patients in
a 2006 uncontrolled trial [18], and since then in AD model mice
[46], stroke model mice [47–49], further AD patients [50–54], post-
stroke patients [55,56], mouse PDmodels [20,57], TBI patients [56],
and a rat TBI model [58]. The routes of administration varied in
ways described by these authors and do not affect the general
Article highlights box
● Excess cerebral levels of the signaling cytokine TNF provide an important
target for therapy against neurodegenerative diseases.
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that constitute repurposing of agents already in use, should be assessed
as part of the approvals process.
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principle. Notably, the Tobinick reports quoted here utilize a novel
perispinal method of getting large molecules through the blood-
brain barrier (BBB) [59,60]. Although an apparent Holy Grail, this
procedure remains unwelcome and unwitnessed by potential
Pharma collaborators or by neurologists, despite being used and
published in open trials andmany clinical reports for 12 years. This
seems irrational, and not in patients’ interests since this perispinal
approach is the conceptual genesis of all the post-2006 publica-
tions quoted in this paragraph. In addition etanercept, and most
like other of the same class plus their biosimilars, constitute drug
repurposing Clearly, much is at stake commercially.
3.2. XPro1595 cf. etanercept
XPro1595 is an exciting, impressively engineered, variant of
TNF [61] that rapidly forms heterotrimers with native TNF to
give a complex termed a dominant negative inhibitor of TNF
because it can no longer bind and signal via TNFR1 or TNFR2.
Importantly, transmembrane TNF signaling remains functional.
This gives XPro1595 a practical advantage over the anti-TNF
biologicals such as etanercept, in that latent infections by
Listeria monocytogenes, Mycobacterium bovis Bacillus Calmette-
Guérin (BCG) and M. tuberculosis can still be suppressed nor-
mally. Administered subcutaneously, it is reported to reduce
harmful effects in 6-OHDA Parkinson’s model [20]. Clearly,
sufficient reached the CSF to have a therapeutic effect, but
this was only about one-thousandth of the plasma level.
Another publication with the same senior author [62] used
the same route of administration for XPro1595 to achieve
a series of positive outcomes in a mouse AD model. From its
molecular weight, it is likely to benefit from the same peri-
spinal route as is employed with etanercept.
Notably, and despite its large size, administering subcuta-
neous etanercept long term has had detectable positive out-
comes in AD and PD. A single-controlled AD patient trial was
conducted in Southampton with subcutaneous etanercept [51].
In this tightly edited version of events, this trial can appear to
have had a negative outcome. However, positive outcomes of
this trial have been presented at international conferences (e.g.
abstract 04–00-12, Alzheimerʼs Association International
Conference Copenhagen, Denmark, 16 July 2014), and dis-
cussed in the first author’s PhD thesis [53]. This covers the
trial more extensively and is compatible with enough subcuta-
neously administered etanercept having entered the brain to
have had worthwhile clinical effects. These data are consistent
with a report, drawn from a particularly large database over
a long period, of subcutaneous chronic use of etanercept to
treat rheumatoid arthritis significantly reducing AD incidence
[52]. A similar pattern, in this case, 78% lower incidence of PD,
was recorded in a large number of patients who received
peripherally administered anti-TNF biologicals to treat inflam-
matory bowel disease, compared with those not receiving this
medication [54]. In our view, therefore, it seems premature to
refer to etanercept as a non-BBB crossing TNF inhibitor [62],
which could be taken to imply that only etanercept, and not
XPro1595, would benefit from perispinal administration [60].
Only when XPro1595 and etanercept are compared directly,
such as done in a mouse stroke model [48], can such judgments
be made. In these studies intravenously administered XPro1595
and etanercept equally improved functional outcomes within
the brain. Given their high molecular weights, both are likely to
demonstrate much more rapid and effective outcomes, with
a considerably lower total dose, when eventually compared on
perispinal administration [60]. We note the accumulated years
of exceptionally wide experience with anti-TNF biologicals such
as etanercept, beginning in the early 1990s, whereas patients
have not yet been exposed to XPro1595. Even so, given its
ability to allow immunity to latent tuberculosis and similar
infectious states to remain intact, eventual therapeutic advan-
tages for this double negative TNF are highly plausible, and we
regard this development as very positive for the field.
3.3. 3,61-dithiothalidomide
Another different approach to reducing excess cerebral TNF
activity has arisen through using 3,61-dithiothalidomide,
a synthetised agent that this group have shown readily enters
the brain and decreases TNF RNA stability [63]. This has led to
a series of closely related and well-reasoned papers [19,64–71].
These convincingly come to the same conclusion as the studies
using anti-TNF biologicals, namely that experimental models of
TBI, AD, post-stroke, and lipopolysaccharide-induced inflamma-
tion all operate through excessive TNF generation. There seems
to be no reason, apart from the name reminding people of the
parent compound, which has harmful properties it does not
share, for this approach not yet to have blossomed.
3.4. Injecting SB623 stem cells into the brain
An additional line of evidence incriminating excess TNF as being
central to the pathogenesis of these conditions arises from
a 2016 uncontrolled trial of surgically implanted SB623 cells
into brains of patients suffering from post-stroke syndromes
[21]. These are modified stem cells from adult bone-marrow-
derived cells that are transiently transfected with a plasmid con-
struct encoding the intracellular domain of human Notch-1.
Positive outcomes occurred, albeit much slower and less dra-
matic in onset, and requiring a more indirect and expensive
delivery system entailing a team of neurosurgeons. Even so,
these outcomes echoed aspects of those achieved in other
uncontrolled trials with a specific anti-TNF biological given by
the novel perispinal route in similar patients some years earlier
[55,56]. The logic of these two approaches is clearly the same –
how to get an anti-TNF effect to where it matters.
The groundwork for this 2016 stem cell study was laid in
2009, when mesenchymal stem cells introduced into a cerebral
ventricle in a rat stroke model, significantly improved function
while enhancing the production of the anti-inflammatory cyto-
kine IL-10 and, crucially, decreasing TNF levels [72]. Thus, the
capacity of these stem cells to improve post-stroke disabilities is
most likely through creating a strong anti-inflammatory milieu,
generated in this case by fibroblast growth factor 2 (FGF2) [73].
Among other activities, this cytokine counters TNF [74]. The
Pharma that owns SB623 cells is rapidly expanding this work
by funding large-controlled trials across the neurological dis-
ease spectrum (e.g. ClinicalTrial.gov Identifiers NCT02448641
and NCT02416492). In contrast, the perispinal etanercept pro-
cedure for countering excess TNF [55,56], the outcome of which
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SB623 cells evidently mimics, yet does not quote [75] has still
not raised any official curiosity within the American Academy of
Neurology [76] despite years of requests, spanning the period
during which the SB623 open trial was done [77], for members
of this Academy to witness it. The numbers treated off-label by
this method and witnessed by experienced people have mush-
roomed since a Californian legal judgment (California Case No.
04–2012-222,007, 22 May 2015) declared that there were suffi-
cient data and research about the drug’s safety and potential
effectiveness to support this treatment continuing. There seems
no scientifically or morally defensible reason why this novel
post-stroke and post-TBI treatment route of administration
[60], its outcomes readily viewable on the internet, and employ-
ing an agent in wide clinical use for decades, has not been
disinterestedly witnessed and evaluated by neurologists over
the past eight years.
3.5. CCR5 inhibition and its implications for TNF in
neurodegenerative disease
More evidence pointing to the significance of excess cerebral
TNF in neurodegenerative diseases comes from a recent study
in which a large-dose daily of maraviroc (Selzentry), an AIDS
medication, was administered intraperitoneally for 8–11 weeks
in mouse post-stroke and post-TBI models [22]. This agent
inhibits CCR5, a chemokine receptor expressed on T cells,
macrophages, microglia, and neurons, and recently associated
with learning and memory [78]. Maraviroc also enhances
motor recovery and reduced cognitive decline in these mice,
along with stabilization of dendritic spines [22], and its pro-
tective activity in the nigrostratum of hemiparkinson monkeys
includes attenuating neuroinflammation [79]. Moreover,
within a large cohort of stroke patients, carriers of a naturally
occurring loss-of-function mutation in CCR5 (CCR5-Δ32) were
reported to exhibit greater recovery of neurological impair-
ment and neurological function.
This remarkable document [22] can perhaps be best charac-
terized as being as fulsome in praise of excess TNF being
a central mechanism for stroke and TBI as is possible without
actually mentioning TNF, or the links their work has with this
cytokine. For example, these human CCR5-Δ32 carriers would
have been predicted, from experience since 2011 of anti-TNF
improving stroke outcomes [47–49,55,56], to recover better from
this condition by virtue of their documented innate poor capa-
city to generate TNF [80]. Maraviroc, an effective anti-TNF agent
[81–84] is shown by these authors [22] to provide useful out-
comes in post-stroke and post-TBI mice. Unaccountably, earlier
reports of other anti-TNF agents operating thus in mice, rats, and
people [47,55,56,58,85] have not been quoted, or compared with
their findings. Moreover, since TNF is known to underlie the loss
of dendritic spines in the experimental cardiac arrest brain [86],
maraviroc can be expected, as shown [22], to preserve them. We
also note that part of the logic discussed for performing these
experiments is associated with shared principles in brain injury
recovery and mechanisms of learning and memory. Prior work in
Carmichael’s laboratory on gamma-aminobutyric acid (GABA)
[87], which reported that reducing extrasynaptic GABA promotes
functional recovery after stroke, is also invoked. Since then,
however, the virology world has reported that excessive TNF
upregulates glutaminase [88], and this enzyme has been shown
to catalyze the conversion of glutamate to GABA [89], as well as
glutamine to glutamate. Wewould, therefore, expect the specific
anti-TNF biological, etanercept, to reduce excess extrasynaptic
GABA and improve learning ability in stroke, since its close
relative, infliximab, causes both of these changes in hepatic
encephalopathy [90]. Finally, we recall that a decade ago para-
sitologists showed that TNF up-regulates CCR5 expression by
CD8 + T lymphocytes and promotes heart tissue damage during
Trypanosoma cruzi infection and that both anti-TNF treatment
[91] and a CCR5 antagonist [92] were beneficial.
3.6. Irisin and its implications for TNF in
neurodegenerative disease
A still further line of evidence incriminating excess cerebral TNF
levels chronically harming brain function arises from recent com-
prehensive publications about the exercise hormone irisin [23,93].
As with the MCC950 study below, neither text measures or dis-
cusses TNF. Nevertheless, it is crucial for the clinical application of
this body of knowledge that we understand the place of irisin in
the pathophysiological interplay that surrounds the role of TNF in
neurodegenerative diseases. Lourenco and co-workers [23] report
irisin, a hormone mainly released from a myokine when skeletal
muscle is strongly exercised, as well as being expressed in the
hippocampus at this time [94], as possessing striking novel activity
in various experimental AD mouse models. In contrast, Young
et al. [93] discuss the principle across the spectrum of neurode-
generative disease. However, the key to both of these texts could
well lie in TNF. Albeit discovered for its role in changing white fat
to brown [95], irisin had, in systemic inflammatory diseases [96–98]
and acquired cerebral injury [99], and well before references 23 or
93 appeared, become appreciated to strongly inhibit TNF and
functionally related cytokines.
Among the many cerebral functions that can be expected
when cerebral TNF is chronically increased, and therefore be
reversed by increasing irisin, are reduced synaptic plasticity [100]
and poor memory [101]. Ample evidence exists that the Aβ these
authors also employed to bring about these changes operates
through enhancing TNF levels [102,103]. It should, therefore,
come as no surprise that Lourenco and co-workers could, respec-
tively, reverse or exacerbate synaptic failure, and memory impair-
ment by either overexpressing or blocking what is effectively
another endogenous anti-TNF agent, irisin. Specifically, increasing
brain levels of irisin by using the adenoviral vector technique
improved synaptic plasticity andmemorydefects inmousemodels
of AD, while reducing irisin levels via a lentiviral vector impaired
synaptic plasticity and memory. Moreover, irisin was low in cere-
brospinal fluid, but not plasma, from AD patients. This opens the
prospect of therapeutically employing recombinant irisin so it
reaches the hippocampus. Given the marked pleiotropic activity
of TNF, and the width of its cerebral influence [13], its link to irisin
invites a re-interpretation of much literature on its effects on brain
function. Even so, the relevance of this work to patients would be
enhanced if a report of the gene encoding FNDC5, the precursor of
irisin, showing, in humans, amutation argued to limit its relevance
to human disease [104] had been discussed. Direct comparisons
between specific anti-TNF biologicals on one hand, and their
biosimilars, bothofwhich are inpresent clinical use, andmaraviroc,
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MCC950, and irisin on the other, are warranted from scientific,
government health funding and patient-need perspectives.
3.7. MCC950 and its implications for TNF in
neurodegenerative disease
An additional line of evidence pointing to the significance of
excess cerebral TNF in neurodegenerative diseases concerns the
uses to which MCC950, a selective NLRP3-inflammasome inhibi-
tor, has been put to in mouse PD models [24]. This synthetic
compound MCC950, administered orally every day, reportedly
blocks inflammasome activation and protects against nigrostria-
tal dopaminergic degeneration. While the authors do not discuss
TNF, ample evidence exists that MCC950, a synthetic compound
originally developed to inhibit interleukin-1β post-translational
processing, also has strong anti-TNF properties [105–109].
NLRP3s are reported, as least in adipocytes [110], to be induced
by TNF.We note that propofol andmangiferin, which the authors
of this new work [24] have recently reported elsewhere [111]
inhibit NLPR3 activity, also suppress TNF production [112,113]. In
addition, XPro1595 (see above), a recombinant double-negative
form of TNF with specific neutralizing activity against native TNF,
produced a very similar outcome [20] in the same 6-hydroxydo-
pamine (6-OHDA) PD model as achieved by Gordon and co-
workers with MCC950 [24].
A comparison between details of outcomes with anti-TNF
biologicals and MCC950, already suggested in a rat stroke model
[108], seems warranted in this and other neurodegenerative
states. Importantly, anti-TNF biologicals have been clinically suc-
cessful, on a large scale, for decades. In contrast, under an alter-
native name, CP-456,773, MCC950 was tested in phase II human
clinical trials for rheumatoid arthritis, but not developed further
because it elevated serum liver enzyme levels in the clinic. The
cause of this liver toxicity signal is not clear, although combined
effects of its metabolically reactive furan moiety and a very high
clinical dose of 1,200 mg per day, two well-known causes of drug-
induced liver injury, might underlie the observed toxicity [114].
Table 1 of this recent review also lists a number of conditions (AD,
inflammatory bowel disease, stroke, and TBI) against which spe-
cific anti-TNF biologicals have shown activity to also be improved
by MCC950. There is not space here to discuss the potential for
complexity between TNF and IL-1, but an impression of it may be
gained by considering the capacity for TNF to induce IL-1 [115],
and IL-1 to induce TNF [116,117]. Moreover, they synergise
[118,119]. These observations imply a synergistically harmful
cycling between these cytokines, and therefore between TLRs
and NLRP3, the receptors that trigger there release, and are con-
sistent with arguments put in place six years ago [38]. From this,
we infer that MCC950, specific anti-TNF biologicals, and XPro1595
are equally valid ways to seek to halt this pathological synergy
across a range of inflammatory diseases. The same can be said of
the SB623 cell, maraviroc, irisin, and MCC590 approaches. They
would reinforce not just each other, but also the other, acknowl-
edged, anti-TNF approaches.
In summary, an intriguing recent series of highly positioned
publications may be seen as efforts to put a distinctive, paten-
table stamp on alternative ways to understanding and treating
the neurodegenerative diseases, by indirectly reducing chroni-
cally excessive cerebral levels of TNF. This fundamental approach
has been extant for over a decade, and appears, in ways that
include these SB623 cell, maraviroc, irisin, and MCC590 publica-
tions, to be coming in out of the cold.
4. Expert opinion
The ultimate goal of this research is to generate for neurode-
generative diseases a therapeutic principle that parallels what
has previously been established for certain chronic systemic
diseases. Persistently high levels of TNF have been known for
many years as worthy targets in treating chronic disease
states. The importance of this target for diseases such as
rheumatoid arthritis, psoriasis, and Crohn’s disease may be
gauged from the massive income specific anti-TNF biologicals
have provided to the pharmaceutical industry over recent
years (Humira (adalimumab), Enbrel (etanercept) and
Remicade (infliximab)) in the graph at https://www.forbes.
com/sites/matthewherper/2015/07/29/the-top-drug-launches-
of-all-time/#46db4cdf6512.). Researchers and industry have
had their sights set, for over a decade, on the potential of
this same approach to generate a similar usefulness, and
income from the neurodegenerative diseases. It has been
evident from the literature over these years that agents direc-
ted at essentially the same target on the other side of the
blood-brain barrier are very likely to help patients. They will
also generate a market for this industry, and therefore a cost
for governments and the public likely to be at least as massive
as those shown on the above graph.
The potential of treating these disease states by neutraliz-
ing excessive cerebral levels of TNF is undoubtedly enormous.
In this commercial age, however, conflict arises. Those with an
ultimate research goal of helping as many patients as possible
look benignly on an example of drug re-purposing provided
by injecting etanercept, an anti-TNF biological with many
FDA-approved clinical applications by a novel route of admin-
istration. This appears to have stopped, in numerous patients,
many post-stroke and post-TBI sequelae in their tracks but has
never attracted backers willing to fund a controlled trial,
except recently the Australian Government. This research
direction has continued for almost a decade, and includes, in
principle, the thalidomide analogues and XPro1595, a double
negative rTNF. It has to be said that the pharmaceutical com-
panies selling etanercept, which is financially threatened by
biosimilars, refused engagement very early on. Clearly, times
are very less patient-orientated than a couple of decades ago.
In 1993, on being advised of success with infliximab, the first
of anti-TNF biologicals, in open studies for rheumatoid arthri-
tis, the company that owns this agent funded a controlled
trial, run in conjunction with the originators of the concept.
This reported a positive Phase III outcome within a year.
Nowadays, times are such that the parent body of the US
medical specialists who collaborate with pharmaceutical com-
panies to research neurodegenerative disease have never to
date, 13 years after the first open trial, even consented to
witness the perispinal injection procedure or its clinical out-
come. Evidently, they see drug repurposing as an anathema to
novel patent-driven research funding and financial success.
Thus, they have put themselves in a position, presumably
rational from their perspective, of actively trying to stop
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something they have never seen, and indeed very rarely
acknowledge exists. Indeed, the court case they initiated to
stop it being used off-label not only failed to do so, but
actually gave its use legal encouragement. In contrast to
neurologists, independent neuroscientists, often following
their own leads, observe and quote this work while building
on it. Already perispinal etanercept outcomes are raising inter-
esting and useful scientific questions, such as how it acts so
quickly, how it can be useful so long after the stroke or TBI
episode, and how its effects last for so long. These are real
outcomes seen in thousands of cases, and measurable by any
witness with a timepiece.
Clearly, the perispinal etanercept deniers have ambitions to
emulate or better this clinical outcome. There is little doubt
that some will eventually be very successful in this, albeit at
a much higher financial cost to governments and individuals
than could have been the case, and at least a decade later
than any agent already in widespread use in the clinic. Thus, it
is important for science and the community that new treat-
ments are compared in efficacy and price to the repurposing
approach outlined above.
Looking ahead, once these post-stroke and post-TBI ques-
tions have practical answers in place, in our view a key ques-
tion, already in many minds, is how well might these advances
make the survival of stroke and TBI more likely. In other words,
will any of the treatments that come out of post-stroke and
post-TBI clinical trials with good reputations prove useful
adjuncts soon after the stroke or traumatic event? The first
week does not lend itself to distinguishing between inevitable
and treatment-induced improvements unless the agent under
consideration is well established to function later, when the
clinical status is stable. Another key question is whether AD
and PD treatment will gain from advances in stroke and TBI
treatment. Their insidious onset and remorseless advance pre-
sents additional problems, but even a temporary respite
through these tools would be instructive scientifically. These
issues merit careful consideration by the neurodegenerative
research community.
Acknowledgments
We gratefully acknowledge valuable advice from Dr Si Ming Man.
Funding
This paper was not funded.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial conflict with
the subject matter or materials discussed in the manuscript. This includes
employment, consultancies, honoraria, stock ownership or options, expert
testimony, grants or patents received or pending, or royalties.
Reviewer Disclosures
Peer reviewers on this manuscript have no relevant financial relationships
or otherwise to disclose.
References
Papers of special note have been highlighted as either of interest (•) or of
considerable interest (••) to readers.
1. Castellani RJ, Perry G. Tau biology, tauopathy, traumatic brain
injury, and diagnostic challenges. J Alzheimers Dis. 2019;67
(2):447–467.
2. Ahmed RM, Devenney EM, Irish M, et al. Neuronal network disin-
tegration: common pathways linking neurodegenerative diseases.
J Neurol Neurosurg Psychiatry. 2016;87(11):1234–1241.
3. Clark IA, Vissel B. Therapeutic implications of how TNF links apoli-
poprotein E, phosphorylated tau, alpha-synuclein, amyloid-beta and
insulin resistance in neurodegenerative diseases. Br J Pharmacol.
2018;175(20):3859–3875.
4. Larson ME, Sherman MA, Greimel S, et al. Soluble alpha-synuclein is
a novel modulator of Alzheimer’s disease pathophysiology.
J Neurosci. 2012;32(30):10253–10266.
5. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43
in frontotemporal lobar degeneration and amyotrophic lateral
sclerosis. Science. 2006;314(5796):130–133.
6. James BD, Wilson RS, Boyle PA, et al. TDP-43 stage, mixed pathol-
ogies, and clinical Alzheimer’s-type dementia. Brain. 2016;139
(11):2983–2993.
7. Josephs KA, Murray ME, Tosakulwong N, et al. Pathological, imaging
and genetic characteristics support the existence of distinct TDP-43
types in non-FTLD brains. Acta Neuropathol. 2019;137(2):227–238.
8. Rohan Z, Rahimi J, Weis S, et al. Screening for alpha-synuclein
immunoreactive neuronal inclusions in the hippocampus allows
identification of atypical MSA (FTLD-synuclein). Acta Neuropathol.
2015;130(2):299–301.
9. Tan RH, Yang Y, Halliday GM. Multiple neuronal pathologies are
common in young patients with pathologically proven frontotem-
poral lobar degeneration. Neuropathol Appl Neurobiol. 2018;44
(5):522-532.
10. Takeda T. Possible concurrence of TDP-43, tau and other proteins
in amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
Neuropathology. 2018;38(1):72–81.
11. Arvin B, Neville LF, Barone FC, et al. The role of inflammation and
cytokines in brain injury. Neurosci Biobehav Rev. 1996;20(3):445–452.
12. Tarkowski E, Liljeroth AM, Minthon L, et al. Cerebral pattern of pro-
and anti-inflammatory cytokines in dementias. Brain Res Bull.
2003;61(3):255–260.
13. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction
and disease. Pharmacol Ther. 2010;128:519–548.
14. Eikelenboom P, Veerhuis R, van Exel E, et al. The early involvement
of the innate immunity in the pathogenesis of late-onset Alzheimer’s
disease: neuropathological, epidemiological and genetic evidence.
Curr Alzheimer Res. 2011;8(2):142–150.
15. Howcroft TK, Campisi J, Louis GB, et al. The role of inflammation in
age-related disease. Aging (Albany NY). 2013;5(1):84–93.
16. Clark IA, Vissel B. Amyloid beta: one of three danger-associated mole-
cules that are secondary inducers of the proinflammatory cytokines
that mediate Alzheimer’s disease. Br J Pharmacol. 2015;172
(15):3714–3727.
17. Degan D, Ornello R, Tiseo C, et al. The role of inflammation in
neurological disorders. Curr Pharm Des. 2018;24(14):1485–1501.
18. Tobinick EL, Gross H, Weinberger A, et al. TNF-alpha modulation for
treatment of Alzheimer’s disease: A 6- month pilot study. Medscape
Gen Med Neurol Neurosurg. 2006;8(2):25.
•• A pilot study that began awareness that the neurodegenera-
tive diseases might prove to be susceptible to treatment with
anti-TNF biologicals.
19. Baratz R, Tweedie D, Rubovitch V, et al. Tumor necrosis factor-alpha
synthesis inhibitor, 3,6ʹ-dithiothalidomide, reverses behavioral
impairments induced by minimal traumatic brain injury in mice.
J Neurochem. 2011;118(6):1032–1042.
20. Barnum CJ, Chen X, Chung J, et al. Peripheral administration of the
selective inhibitor of soluble tumor necrosis factor (TNF) XPro(R)
1595 attenuates nigral cell loss and glial activation in 6-OHDA
hemiparkinsonian rats. J Parkinsons Dis. 2014;4(3):349–360.
540 I. A. CLARK AND B. VISSEL
21. Steinberg GK, Kondziolka D, Wechsler LR, et al. Clinical outcomes of
transplanted modified bone marrow-derived mesenchymal stem
cells in stroke: A phase 1/2a study. Stroke. 2016;47(7):1817–1824.
22. Joy MT, Ben Assayag E, Shabashov-Stone D, et al. CCR5 is
a therapeutic target for recovery after stroke and traumatic brain
injury. Cell. 2019;176(5):1143–1157.e1113.
23. Lourenco MV, Frozza RL, de Freitas GB, et al. Exercise-linked
FNDC5/irisin rescues synaptic plasticity and memory defects in
Alzheimer’s models. Nat Med. 2019;25(1):165–175.
24. Gordon R, Albornoz EA, Christie DC, et al. Inflammasome inhibition
prevents alpha-synuclein pathology and dopaminergic neurode-
generation in mice. Sci Transl Med. 2018;10(465):1–12.
25. Janeway CA Jr. Pillars article: approaching the asymptote?
Evolution and revolution in immunology. Cold Spring Harb Symp
Quant Biol. 1989;54(9):1–13.
•• This review began the DAMP and PAMP overview of under-
standing innate imunity and chronic inflammatory disease.
26. Matzinger P. Tolerance, danger, and the extended family. Annu Rev
Immunol. 1994;12:991–1045.
•• This review crucially extended the above concepts by Janeway.
27. Schneider DS, Hudson KL, Lin TY, et al. Dominant and recessive
mutations define functional domains of toll, a transmembrane pro-
tein required for dorsal-ventral polarity in the Drosophila embryo.
Genes Dev. 1991;5(5):797–807.
28. Oppenheim JJ, Tewary P, de la Rosa G, et al. Alarmins initiate host
defense. Adv Exp Med Biol. 2007;601:185–194.
29. Bertheloot D, Latz E. HMGB1, IL-1alpha, IL-33 and S100 proteins:
dual-function alarmins. Cell Mol Immunol. 2017;14(1):43–64.
30. Walko TD, Bola RA, Hong JD, et al. Cerebrospinal fluid mitochon-
drial DNA: a novel DAMP in pediatric traumatic brain injury. Shock.
2014;41(6):499–503.
31. Dosunmu R, Alashwal H, Zawia NH. Genome-wide expression and
methylation profiling in the aged rodent brain due to early-life Pb
exposure and its relevance to aging. Mech Ageing Dev. 2012;133
(6):435–443.
32. Li Q, Yu B, Yang P. Hypoxia-induced HMGB1 in wound tissues
promotes the osteoblast cell proliferation via activating ERK/JNK
signaling. Int J Clin Exp Med. 2015;8(9):15087–15097.
33. Calderon-Garciduenas L, Solt AC, Henriquez-Roldan C, et al. Long-
term air pollution exposure is associated with neuroinflammation,
an altered innate immune response, disruption of the blood-brain
barrier, ultrafine particulate deposition, and accumulation of amy-
loid beta-42 and alpha-synuclein in children and young adults.
Toxicol Pathol. 2008;36(2):289–310.
34. Kafoury RM, Madden MC. Diesel exhaust particles induce the over
expression of tumor necrosis factor-alpha (TNF-alpha) gene in
alveolar macrophages and failed to induce apoptosis through
activation of nuclear factor-kappaB (NF-kappaB). Int J Environ Res
Public Health. 2005;2(1):107–113.
35. Gianni T, Leoni V, Campadelli-Fiume G. Type I interferon and
NF-kappaB activation elicited by herpes simplex virus gH/gL via
alphavbeta3 integrin in epithelial and neuronal cell lines. J Virol.
2013;87(24):13911–13916.
36. Itzhaki RF, Lathe R, Balin BJ, et al. Microbes and Alzheimer’s disease.
J Alzheimers Dis. 2016;51(4):979–984.
37. Patel S. Danger-associated molecular patterns (DAMPs): the deriva-
tives and triggers of inflammation. Curr Allergy Asthma Rep.
2018;18(11):63.
38. Hanamsagar R, Hanke ML, Kielian T. Toll-like receptor (TLR) and
inflammasome actions in the central nervous system. Trends
Immunol. 2012;33(7):333–342.
39. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action,
role in disease, and therapeutics. Nat Med. 2015;21(7):677–687.
40. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind
comparison of chimeric monoclonal antibody to tumour necrosis
factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet.
1994;344(8930):1105–1110.
41. Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel
inflammation: toward a cytokine-based disease taxonomy. Nat
Med. 2013;19(7):822–824.
• This review greatly widened awareness of how broadly applic-
able is the concept of cytokine-based disease.
42. Clark IA, Alleva LE, Mills AC, et al. Pathogenesis of malaria and
clinically similar conditions. Clin Microbiol Rev. 2004;17(3):509–539.
43. Castellani RJ, Lee HG, Zhu X, et al. Alzheimer disease pathology as
a host response. J Neuropathol Exp Neurol. 2008;67(6):523–531.
44. Morris GP, Clark IA, Vissel B. Questions concerning the role of
amyloid-beta in the definition, aetiology and diagnosis of
Alzheimer’s disease. Acta Neuropathol. 2018;136(5):663–689.
45. Mullane K, Williams M. The de-Alzheimerization of age-related
dementias: implications for drug targets and approaches to effec-
tive therapeutics. Curr Opin Pharmacol. 2019;11:1–14.
46. Shi JQ, Shen W, Chen J, et al. Anti-TNF-alpha reduces amyloid
plaques and tau phosphorylation and induces CD11c-positive
dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain
Res. 2011;1368(12):239–247.
47. Sumbria RK, Boado RJ, Pardridge WM. Brain protection from stroke
with intravenous TNFalpha decoy receptor-Trojan horse fusion
protein. J Cereb Blood Flow Metab. 2012;32(10):1933–1938.
48. Clausen B, Degn M, Martin N, et al. Systemically administered
anti-TNF therapy ameliorates functional outcomes after focal cere-
bral ischemia. J Neuroinflammation. 2014;11(1):203.
49. Bonetti NR, Diaz-Canestro C, Liberale L, et al. Tumour Necrosis
factor-alpha inhibition improves stroke outcome in a mouse
model of rheumatoid arthritis. Sci Rep. 2019;9(1):2173.
50. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer’s
disease following perispinal etanercept administration. J Neuroin-
flammation. 2008;5:2.
51. Butchart J, Brook L, Hopkins V, et al. Etanercept in Alzheimer
disease: A randomized, placebo-controlled, double-blind, phase 2
trial. Neurology. 2015;84:2161–2168.
52. Chou RC, Kane M, Ghimire S, et al. Treatment for rheumatoid
arthritis and risk of Alzheimer’s disease: A nested case-control
analysis. CNS Drugs. 2016;30:1111–1120.
53. Butchart JW. Systemic inflammation and sickness behaviour in
Alzheimer’s disease [PhD Thesis]. University of Southhampton;
2017.
54. Peter I, Dubinsky M, Bressman S, et al. Anti–tumor necrosis factor
therapy and incidence of Parkinson disease among patients with
inflammatory bowel disease. JAMA Neurol. 2018;75(8):939–946.
55. Tobinick E. Rapid improvement of chronic stroke deficits after
perispinal etanercept: three consecutive cases. CNS Drugs.
2011;25(2):145–155.
•• The first evidence that post-stroke syndromes could be dra-
matically influenced by anti-TNF biologicals.
56. Tobinick E, Kim NM, Reyzin G, et al. Selective TNF inhibition for
chronic stroke and traumatic brain injury: an observational study
involving 629 consecutive patients treated with perispinal
etanercept. CNS Drugs. 2012;26(12):1051–1070.
57. Zhou QH, Boado RJ, Hui EK, et al. Brain-penetrating tumor necrosis
factor decoy receptor in the mouse. Drug Metab Dispos. 2011;39
(1):71–76.
58. Chio CC, Chang CH, Wang CC, et al. Etanercept attenuates trau-
matic brain injury in rats by reducing early microglial expression of
tumor necrosis factor-alpha. BMC Neurosci. 2013;14(1):33.
59. Tobinick E, Vega CP. The cerebrospinal venous system: anatomy,
physiology, and clinical implications. MedGenMed. 2006;8(1):53.
60. Tobinick E. Perispinal etanercept advances as a neurotherapeutic.
Expert Rev Neurother. 2018;18(6):453–455.
61. Steed PM, Tansey MG, Zalevsky J, et al. Inactivation of TNF signaling
by rationally designed dominant-negative TNF variants. Science.
2003;301(5641):1895–1898.
62. MacPherson KP, Sompol P, Kannarkat GT, et al. Peripheral adminis-
tration of the soluble TNF inhibitor XPro1595 modifies brain
immune cell profiles, decreases beta-amyloid plaque load, and
rescues impaired long-term potentiation in 5xFAD mice.
Neurobiol Dis. 2017;102:81–95.
63. Greig NH, Giordano T, Zhu X, et al. Thalidomide-based TNF-alpha
inhibitors for neurodegenerative diseases. Acta Neurobiol Exp.
2004;64(1):1–9.
EXPERT REVIEW OF NEUROTHERAPEUTICS 541
64. Zhu X, Giordano T, Yu QS, et al. Thiothalidomides: novel isosteric
analogues of thalidomide with enhanced TNF-alpha inhibitory
activity. J Med Chem. 2003;46(24):5222–5229.
65. Frankola KA, Greig NH, Luo W, et al. Targeting TNF-alpha to eluci-
date and ameliorate neuroinflammation in neurodegenerative
diseases. CNS Neurol Disord Drug Targets. 2011;10(3):391–403.
66. Belarbi K, Jopson T, Tweedie D, et al. TNF-alpha protein synthesis
inhibitor restores neuronal function and reverses cognitive deficits
induced by chronic neuroinflammation. J Neuroinflammation.
2012;9(1):23.
67. Gabbita SP, Srivastava MK, Eslami P, et al. Early intervention with
a small molecule inhibitor for tumor necrosis factor-alpha prevents
cognitive deficits in a triple transgenic mouse model of Alzheimer’s
disease. J Neuroinflammation. 2012;9:99.
68. Russo I, Caracciolo L, Tweedie D, et al. 3,6ʹ-Dithiothalidomide, a new
TNF-alpha synthesis inhibitor, attenuates the effect of Abeta1-42
intracerebroventricular injection on hippocampal neurogenesis and
memory deficit. J Neurochem. 2012;122(6):1181–1192.
69. Tweedie D, Ferguson RA, Fishman K, et al. Tumor necrosis factor-
alpha synthesis inhibitor 3,6ʹ-dithiothalidomide attenuates markers
of inflammation, Alzheimer pathology and behavioral deficits in
animal models of neuroinflammation and Alzheimer’s disease.
J Neuroinflammation. 2012;9:106.
70. Yoon JS, Lee JH, Tweedie D, et al. 3,6ʹ-dithiothalidomide improves
experimental stroke outcome by suppressing neuroinflammation.
J Neurosci Res. 2013;91(5):671–680.
71. Batsaikhan B, Wang JY, Scerba MT, et al. Post-Injury neuroprotec-
tive effects of the thalidomide analog 3,6ʹ-dithiothalidomide on
traumatic brain injury. Int J Mol Sci. 2019;20(3):E502.
72. Liu N, Chen R, Du H, et al. Expression of IL-10 and TNF-alpha in rats
with cerebral infarction after transplantation with mesenchymal
stem cells. Cell Mol Immunol. 2009;6(3):207–213.
73. Aizman I, Vinodkumar D, McGrogan M, et al. Cell injury-induced
release of fibroblast growth factor 2: relevance to intracerebral
mesenchymal stromal cell transplantations. Stem Cells Dev. 2015;24
(14):1623–1634.
74. Yu Y, He J, Li S, et al. Fibroblast growth factor 21 (FGF21) inhibits
macrophage-mediated inflammation by activating Nrf2 and sup-
pressing the NF-kappaB signaling pathway. Int Immunopharmacol.
2016;38:144–152.
75. Clark IA. Letter by Clark regarding article, “Clinical outcomes of
transplanted modified bone marrow-derived mesenchymal stem
cells in stroke: A phase 1/2a study”. Stroke. 2016;47(12):e268.
76. Clark IA. Editorial: an unsound AAN practice advisory on poststroke
etanercept. Expert Rev Neurother. 2017;17(3):215–217.
77. Steinberg GK, Kondziolka D, Bates D. Response by Steinberg et al
to letter regarding article, “Clinical outcomes of transplanted mod-
ified bone marrow-derived mesenchymal stem cells in stroke:
a phase 1/2A study”. Stroke. 2016;47(12):e269.
78. Zhou M, Greenhill S, Huang S, et al. CCR5 is a suppressor for cortical
plasticity and hippocampal learning and memory. Elife. 2016;5.
79. Mondal S, Rangasamy SB, Roy A, et al. Low-dose maraviroc, an
antiretroviral drug, attenuates the infiltration of T cells into the
central nervous system and protects the nigrostriatum in hemipar-
kinsonian monkeys. J Immunol. 2019.
80. Muntinghe FL, Carrero JJ, Navis G, et al. TNF-alpha levels are not
increased in inflamed patients carrying the CCR5 deletion 32.
Cytokine. 2011;53(1):16–18.
81. Ashraf T, Jiang W, Hoque MT, et al. Role of anti-inflammatory com-
pounds in human immunodeficiency virus-1 glycoprotein120-
mediated brain inflammation. J Neuroinflammation. 2014;11:91.
82. Beliakova-Bethell N, Jain S, Woelk CH, et al. Maraviroc intensification
in patients with suppressed HIV viremia has limited effects on CD4+
T cell recovery and gene expression. Antiviral Res. 2014;107:42–49.
83. Tiraboschi JM, Munoz-Moreno JA, Puertas MC, et al. Viral and
inflammatory markers in cerebrospinal fluid of patients with
HIV-1-associated neurocognitive impairment during antiretroviral
treatment switch. HIV Med. 2015;16(6):388–392.
84. Yuan J, Ren HY, Shi YJ, et al. In vitro immunological effects of
blocking CCR5 on T cells. Inflammation. 2015;38(2):902–910.
85. Cheong CU, Chang CP, Chao CM, et al. Etanercept attenuates
traumatic brain injury in rats by reducing brain TNF- alpha contents
and by stimulating newly formed neurogenesis. Mediators
Inflammation. 2013;620837:2013.
86. Meissner A, Visanji NP, MomenMA, et al. Tumor Necrosis Factor-alpha
underlies loss of cortical dendritic spine density in a mouse model of
congestive heart failure. J Am Heart Assoc. 2015;4(5):1–17.
87. Clarkson AN, Huang BS, Macisaac SE, et al. Reducing excessive
GABA-mediated tonic inhibition promotes functional recovery
after stroke. Nature. 2010;468(7321):305–309.
88. Chen CJ, Ou YC, Chang CY, et al. Glutamate released by Japanese
encephalitis virus-infected microglia involves TNF-alpha signaling
and contributes to neuronal death. Glia. 2012;60(3):487–501.
89. Nanga RP, DeBrosse C, Singh A, et al. Glutaminase catalyzes reac-
tion of glutamate to GABA. Biochem Biophys Res Commun.
2014;448(4):361–364.
90. Dadsetan S, Balzano T, Forteza J, et al. Infliximab reduces periph-
eral inflammation, neuroinflammation, and extracellular GABA in
the cerebellum and improves learning and motor coordination in
rats with hepatic encephalopathy. J Neuroinflammation. 2016;
13(1):245.
91. Kroll-Palhares K, Silverio JC, Silva AA, et al. TNF/TNFR1 signaling
up-regulates CCR5 expression by CD8+ T lymphocytes and pro-
motes heart tissue damage during Trypanosoma cruzi infection:
beneficial effects of TNF-alpha blockade. Mem Inst Oswaldo Cruz.
2008;103(4):375–385.
92. Medeiros GA, Silverio JC, Marino AP, et al. Treatment of chronically
Trypanosoma cruzi-infected mice with a CCR1/CCR5 antagonist
(Met-RANTES) results in amelioration of cardiac tissue damage.
Microbes Infect. 2009;11(2):264–273.
93. Young MF, Valaris S, Wrann CD. A role for FNDC5/Irisin in the
beneficial effects of exercise on the brain and in neurodegenerative
diseases. Prog Cardiovasc Dis. 2019;62(2):172–178.
94. Wrann CD, White JP, Salogiannnis J, et al. Exercise induces hippo-
campal BDNF through a PGC-1alpha/FNDC5 pathway. Cell Metab.
2013;18(5):649–659.
95. Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-alpha-dependent
myokine that drives brown-fat-like development of white fat and
thermogenesis. Nature. 2012;481(7382):463–468.
96. Mazur-Bialy AI, Bilski J, Pochec E, et al. New insight into the direct
anti-inflammatory activity of a myokine irisin against proinflamma-
tory activation of adipocytes. Implication for exercise in obesity.
J Physiol Pharmacol. 2017;68(2):243–251.
97. Shao L, Meng D, Yang F, et al. Irisin-mediated protective effect on
LPS-induced acute lung injury via suppressing inflammation and
apoptosis of alveolar epithelial cells. Biochem Biophys Res
Commun. 2017;487(2):194–200.
98. Narayanan SA, Metzger CE, Bloomfield SA, et al. Inflammation-
induced lymphatic architecture and bone turnover changes are
ameliorated by irisin treatment in chronic inflammatory bowel
disease. Faseb J. 2018;32(9):4848–4861.
99. Li DJ, Li YH, Yuan HB, et al. The novel exercise-induced hormone
irisin protects against neuronal injury via activation of the Akt and
ERK1/2 signaling pathways and contributes to the neuroprotection
of physical exercise in cerebral ischemia. Metabolism. 2017;68:31–42.
100. Maggio N, Vlachos A. Tumor necrosis factor (TNF) modulates synap-
tic plasticity in a concentration-dependent manner through intracel-
lular calcium stores. J Mol Med (Berl). 2018;96(10):1039–1047.
101. Habbas S, Santello M, Becker D, et al. Neuroinflammatory TNFalpha
impairs memory via astrocyte signaling. Cell. 2015;163(7):1730–1741.
102. Wang QW, Wu JQ, Rowan MJ, et al. Beta-amyloid inhibition of
long-term potentiation is mediated via tumor necrosis factor. Eur
J Neurosci. 2005;22(11):2827–2832.
• First publication to document that harmful effects of Aβ in brain
arise from its capacity to act as a DAMP and thus induce TNF.
103. Rowan MJ, Klyubin I, Wang Q, et al. Synaptic memory mechanisms:
alzheimer’s disease amyloid beta-peptide-induced dysfunction.
Biochem Soc Trans. 2007;35(Pt 5):1219–1223.
104. Raschke S, Elsen M, Gassenhuber H, et al. Evidence against
a beneficial effect of irisin in humans. PLoS One. 2013;8(9):e73680.
542 I. A. CLARK AND B. VISSEL
105. Ismael S, Zhao L, Nasoohi S, et al. Inhibition of the
NLRP3-inflammasome as a potential approach for neuroprotection
after stroke. Sci Rep. 2018;8(1):5971.
106. Krishnan SM, Ling YH, Huuskes BM, et al. Pharmacological inhibition of
the NLRP3 inflammasome reduces blood pressure, renal damage and
dysfunction in salt-sensitive hypertension. Cardiovasc Res. 2018;19(6):
E1712.
107. Perera AP, Fernando R, Shinde T, et al. MCC950, a specific small
molecule inhibitor of NLRP3 inflammasome attenuates colonic
inflammation in spontaneous colitis mice. Sci Rep. 2018;8(1):8618.
108. Qi Y, Klyubin I, Cuello AC, et al. NLRP3-dependent synaptic plasti-
city deficit in an Alzheimer’s disease amyloidosis model in vivo.
Neurobiol Dis. 2018;114:24–30.
109. Luo Y, Lu J, Ruan W, et al. MCC950 attenuated early brain injury by
suppressing NLRP3 inflammasome after experimental SAH in rats.
Brain Res Bull. 2019;146:320–326.
110. Furuoka M, Ozaki K, Sadatomi D, et al. TNF-alpha induces caspase-1
activation independently of simultaneously induced NLRP3 in
3T3-L1 cells. J Cell Physiol. 2016;231(12):2761–2767.
111. Albornoz EA, Woodruff TM, Gordon R. Inflammasomes in CNS
diseases. Exp Suppl. 2018;108:41–60.
112. Meng T, Yu J, Lei Z, et al. Propofol reduces lipopolysaccharide-induced,
NADPH oxidase (NOX 2) mediated TNF- alpha and IL-6 production in
macrophages. Clin Dev Immunol. 2013;325481:2013.
113. Fan K, Ma J, Xiao W, et al. Mangiferin attenuates blast-induced
traumatic brain injury via inhibiting NLRP3 inflammasome. Chem
Biol Interact. 2017;271:15–23.
114. Mangan MSJ, Olhava EJ, Roush WR, et al. Targeting the NLRP3
inflammasome in inflammatory diseases. Nat Rev Drug Discov.
2018;17(9):688.
115. Franchi L, Eigenbrod T, Núñez G. Cutting edge: TNF-alpha med-
iates sensitization to ATP and silica via the NLRP3 inflammasome
in the absence of microbial stimulation. J Immunol. 2009;183
(2):792–796.
116. Ikejima T, Okusawa S, Ghezzi P, et al. Interleukin-1 induces tumor
necrosis factor (TNF) in human peripheral blood mononuclear cells
in vitro and a circulating TNF-like activity in rabbits. J Infect Dis.
1990;162(1):215–223.
117. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflam-
masome activation interferes with insulin signaling. Nat Immunol.
2011;12(5):408–415.
118. Dinarello CA, Okusawa S, Gelfand JA. Interleukin-1 induces a
shock-like state in rabbits: synergism with tumor necrosis factor
and the effect of cyclooxygenase inhibition. Prog Clin Biol Res.
1989;286:243–263.
119. Rockett KA, Awburn MM, Rockett EJ, et al. Tumor necrosis factor
and interleukin-1 synergy in the context of malaria pathology. Am
J Trop Med Hyg. 1994;50(6):735–742.
EXPERT REVIEW OF NEUROTHERAPEUTICS 543
